Src Inhibitor 1 5 mg | 100.00%
TargetMol
Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.
More Information Supplier PageSrc Inhibitor 1
Search Results
Src Inhibitor 1 50 mg | 100.00%
TargetMol
Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.
More Information Supplier PageSrc Inhibitor 1
Src Inhibitor 1 25 mg | 100.00%
TargetMol
Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.
More Information Supplier PageSrc Inhibitor 1
Src Inhibitor 1 10 mg | 100.00%
TargetMol
Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor.
More Information Supplier PageSrc Inhibitor 1
Compound 401 5 mg | 99.76%
TargetMol
Compound 401 is a synthetic DNA-PK inhibitor (IC50 = 0.28 μM) that also targets mTOR but not PI3K.
More Information Supplier PageCompound 401
TB5 25 mg | 99.82%
TargetMol
TB5
TB5 50 mg | 99.82%
TargetMol
TB5
Solcitinib 5 mg | Purity Not Available
TargetMol
Solcitinib (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus erythematosus.
More Information Supplier PageSolcitinib
Solcitinib 50 mg | Purity Not Available
TargetMol
Solcitinib (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus erythematosus.
More Information Supplier PageSolcitinib
Solcitinib 10 mg | Purity Not Available
TargetMol
Solcitinib (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and systemic lupus erythematosus.
More Information Supplier PageSolcitinib